Cadila is a well known research-oriented, technology-driven pharmaceutical company focused on the research areas of biotechnology, formulations and Active Pharmaceutical Ingredients (APIs), etc. It has marketing offices in more than 4 countries and has significant presence in over 45
countries.

It is into the operations of softgel, telecommunications, hospital disposables, instrumentations and diagnostics, etc. Cadila is among the leading pharma companies with over 400 multi-dimensional formulations of major therapeutics groups in human and over 15 in animal health. Cadila has a strong formulation development base and is the first manufacturer of Immuvac, a unique immunomodulator.
In Asia, it is the unrivaled manufacturer of ‘SULFOLANE’ (Tetramethylene Sulfone). Its Bulk Actives (APIs) manufacturing facility is approved under ISO 9002 and it offers facilities for contract research. It has achieved leadership in Indian Generic market as well as in Distribution management.

The R&D facility of Cadila is spread in an area of 45,000 Sq.ft. and has human resources of 150
scientists. It has collaboration with more than 30 leading R&D centers in the country. It has introduced RABEPRAZOLE and FOSINOPRIL formulations in India. Its strong marketing & sales team consists of 2, 37318 pharmacies 1900 wholesalers, 25 C&S agents, and 1,300 field employees

Cadila has the following brands:

  • Envas
  • Aciloc
  • Lmx, Symbiotik, Clax
  • Rabeloc, RD, Zaso, Mixulin, Montelast and Nodon

Corporate & Registered Office
CADILA CORPORATE CAMPUS

Sarkhej-Dholka Road,
Bhat, Ahmedabad-382 210, INDIA.
Phone: +91-2718-225001 (15 Lines)
Fax: +91-2718-225039
e-mail: website@cadilapharma.co.in

Quarterly Results of Cadila

Quarterly Results (Rs. in Millions)
Dec 2006 (3 rd quarter) Sept 2006(2nd quarter) Dec 2005(3 rd quarter)
Sales Turnover 3749 4037 3328
Other Income 281 194 179
Total Income 4030 4231 3507
Total Expenditure 3199 3287 2773
Operating Profit 831 944 734
Interest 44 32 91
Gross Profit 787 912 643
Depreciation 172 167 153
Tax 90 90 48
Reported PAT 525 655 429

*Source: economictimes.indiatimes.com

Quarterly Results (in %)
% Change (Over Sep 2006) % Change (Over Dec 2005)
Sales Turnover -7.13 12.65
Other Income 44.85 56.98
Total Income -4.75 14.91
Total Expenditure -2.68 15.36
Operating Profit -11.97 13.22
Interest 37.5 -51.65
Gross Profit -13.71 22.4
Depreciation 2.99 12.42
Tax
Reported PAT -19.85 22.38

*Source: economictimes.indiatimes.com

Annual Results of Cadila:

Annual Unaudited Results (Rs. in Millions)
(12 Months) (12 Months) % Changes
Sales Turnover 11253.00 11160.00 0.83
Other Income 785 925 -15.14
Total Income 12038.00 12085.00 -0.39
Total Expenditure 9643.00 9598.00 0.47
Operating Profit 2395.00 2487.00 -3.7
Interest 202 232 -12.93
Gross Profit 2193.00 2255.00 -2.75
Depreciation 565 531 6.4
Tax 190 222 -14.41
Reported PAT 1314.00 1411.00 -6.87

*Source: economictimes.indiatimes.com